ATE106250T1 - Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität. - Google Patents

Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität.

Info

Publication number
ATE106250T1
ATE106250T1 AT88305934T AT88305934T ATE106250T1 AT E106250 T1 ATE106250 T1 AT E106250T1 AT 88305934 T AT88305934 T AT 88305934T AT 88305934 T AT88305934 T AT 88305934T AT E106250 T1 ATE106250 T1 AT E106250T1
Authority
AT
Austria
Prior art keywords
antibody
biological activity
molecule
complex
inactivation
Prior art date
Application number
AT88305934T
Other languages
English (en)
Inventor
Ezekiel Y Shami
Aser Rothstein
Mohabir Ramjeesingh
Original Assignee
Hybrisens Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrisens Ltd filed Critical Hybrisens Ltd
Application granted granted Critical
Publication of ATE106250T1 publication Critical patent/ATE106250T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82Asparaginase (3.5.1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88305934T 1987-07-07 1988-06-30 Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität. ATE106250T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7186187A 1987-07-07 1987-07-07
US18253088A 1988-04-18 1988-04-18
US20574888A 1988-06-21 1988-06-21

Publications (1)

Publication Number Publication Date
ATE106250T1 true ATE106250T1 (de) 1994-06-15

Family

ID=27371979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88305934T ATE106250T1 (de) 1987-07-07 1988-06-30 Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität.

Country Status (7)

Country Link
EP (1) EP0298654B1 (de)
JP (1) JPH01138461A (de)
AT (1) ATE106250T1 (de)
AU (1) AU1865288A (de)
DE (1) DE3889783T2 (de)
DK (1) DK375188A (de)
ES (1) ES2056108T3 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
ES2148144T3 (es) * 1990-11-20 2000-10-16 Dade Behring Marburg Gmbh Procedimiento para la estabilizacion de conjugados de enzima.
AU6953796A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled cellulolytic activity
AU6849696A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled proteolytic activity
AU6849796A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled enzymatic activity
AU6777296A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled lipolytic activity
WO1998007816A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising oxido-reductase antibody
WO1998007818A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising antibody controlled amylolytic activity
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
JPWO2005094881A1 (ja) * 2004-03-30 2008-02-14 武田薬品工業株式会社 抗体医薬
EP1841452B8 (de) * 2004-10-08 2014-06-11 Domantis Limited Einzel-domän antikörper gegen tnfr1 und verfahren und deren verwendungen
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
ATE58479T1 (de) * 1985-12-28 1990-12-15 Nippon Hypox Lab Inc Albumin-komplex.
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides

Also Published As

Publication number Publication date
JPH01138461A (ja) 1989-05-31
DK375188D0 (da) 1988-07-06
DE3889783D1 (de) 1994-07-07
ES2056108T3 (es) 1994-10-01
DE3889783T2 (de) 1994-09-08
AU1865288A (en) 1989-01-12
DK375188A (da) 1989-01-08
EP0298654A3 (en) 1990-02-07
EP0298654B1 (de) 1994-06-01
EP0298654A2 (de) 1989-01-11

Similar Documents

Publication Publication Date Title
DE3889783D1 (de) Verwendung von Antikörper-Antigen-Wechselwirkung zum Schutz oder Modulation der biologischen Aktivität.
ATE82510T1 (de) Verfahren zur inaktivierung von viren.
ATE68015T1 (de) Herstellung von mikrobieller zellulose.
ATE42206T1 (de) Verfahren und zusammensetzung zur gleichzeitigen reinigung und desinfektion von kontaktlinsen.
SE7707599L (sv) Immobiliserad, katalytiskt aktiv substans och sett for framstellning derav
ATE525390T1 (de) Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
ATE1296T1 (de) Substratzusammensetzung und ihre verwendung.
DE68911426D1 (de) Verfahren zur Verarbeitung von organischem Material.
DK0645007T3 (da) Sensor til optisk analyse
ATE95694T1 (de) Verwendung von bezafibrat zur behandlung von diabetes.
DE59009532D1 (de) Verwendung von 1-Arylsemicarbaziden zur Stabilisierung von Enzymsubstraten, entsprechende Verfahren und diagnositsches Mittel enthaltend einen solchen Stabilisator.
ATE129012T1 (de) Enzymatische oxidation von ceph c zu glutaryl-7- aminocephalosporansäure.
ATE36557T1 (de) Verfahren zur bestimmung der wirksamkeit von substraten oder enzymen.
ES478533A1 (es) Un procedimiento para eliminar melamina de liquidos que con-tienen melamina.
FI931554A0 (fi) Foerfarande foer utvinning av enzymer fraon proenzymer
ATE54065T1 (de) Katalysatorherstellung.
BG33588A3 (bg) Метод за получаване на глюкозо-изомеризиращ ензим
ATE125713T1 (de) Verfahren zur inaktivierung der biologischen aktivität von dna.
DK710588D0 (da) Enzym samt fremgangsmaade til enzymatisk hydrolyse af alfa-aminoadipinyl-monoaminoforbindelser
ATE22702T1 (de) Herstellung von glucosedehydrogenase.
ATE10067T1 (de) Verfahren zur reaktivierung von vanadium enthaltenden oxidationskatalysatoren.
BG89739A (bg) Метод за повишаване ензимната активност и синтезната продуктивност на организми
RU1838311C (ru) Способ получени 2-(3-пиридил)тетрагидротиапиранкарботиоамид-2-оксида-1(1R, 2R)
SE8600987L (sv) Forfarande for framstellning av ett protein- koncentrat ur helblod
DE69730313D1 (de) Methode zur inaktivierung von proteinen der ras-unterfamilie und verbindungen dafuer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties